Novartis CEO Joseph Jimenez wrote a letter to India Commerce and Industry Minister Anand Sharma objecting to statements attributed to Sharma that implied Novartis is pleased with India's intellectual property laws. An aide to Sharma defended the nation's patent policies and responded that the minister had been referring to another drugmaker. The incident reflects ongoing acrimony between India and international drugmakers over patents, according to this article.

Related Summaries